Pharmacogenetic Phenotyping and Genotyping: Present Status and Future Potential

Clinical Pharmacokinetics

Volumn 26, Issue 1, 1994, Pages 59-70

  Gonzalez, Frank J ^a,b,c,d   Idle, Jeffrey R ^a,b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Genotype Ltd ^*  (United Kingdom)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALDEHYDE DEHYDROGENASE; ARYLESTERASE; CYTOCHROME P450 ISOENZYME; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; QUERCETIN; SULFOTRANSFERASE; THIOPURINE METHYLTRANSFERASE; UNSPECIFIC MONOOXYGENASE;

DRUG METABOLISM; ENZYME ACTIVITY; GENOTYPE; HUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYMES; GENOTYPE; HUMAN; PHENOTYPE; POLYMORPHISM (GENETICS);

EID: 0027983085     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199426010-00005     Document Type: Review

References (69)

1. Pharmacogenetics of alcohol metabolism and alcholism
2. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators
3. Cytochrome P450 hPCN3, a novel P450 III? gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine
4. Molecular basis for the polymorphic forms of serum paraoxonase/arylesterase: glutamine or arginine at position 191, for respective A or B allozymes
5. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer
6. Molecular mechanism of slow acetylation of drugs and carcinogens in humans
7. Interindividual variation in the activation and inactivation metabolic pathways of cyclophosphamide
8. Debrisoquine/spartein hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population
9. Clinical implications of variable antiarrythmic drug metabolism
10. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites
11. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence
12. Comparison of a novel thin-layer chromatography-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine
13. Human pharmacogenetics of nitrogen oxidations
14. Genetically variable metabolism of antidepressants and neuroleptic drugs in man
15. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenoytpes
16. Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds
17. Homozygous deletion of the glutathione S-transferase M1 (GSTM1) gene is a risk factor in bladder cancer
18. Familial deficiency of dehydropyrimidine dehydrogenase biochemical basis for familial pyrimidemia and seven 5-fluorouracil-induced toxicity
19. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects
20. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to descriminate reliably heterozygous and homozygous extensive metabolizers
21. Molecular genetics of the debrisoquine/sparteine polymorphism
22. Evolution of the P450 gene superfamily: animal-plant ‘warfare’, molecular drive and human genetic differences in drug oxidation
23. Molecular genetics of the N-acetyltransferases
24. Mechanism-based inactivation of human liver cytochrome P450 IIIA4 by gestadene
25. Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects
26. Phenotypical deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients
27. Detection of human DNA mutations with nonradioactive allele-specific oligonucleotide probes
28. Pharmacogenetics: can the therapeutic key objective be accomplished
29. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence
30. N-Acetyltransferase polymorphism: comparison of phenotype and genotype in humans
31. Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA
32. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol
33. The pharmacogenetics of chemical carcinogenesis
34. Variability in nifedipine kinetics and dynamics: a new oxidation polymorphism in man
35. Human serum paraoxonase/arylesterase
36. Molecular genetics of the flavin-dependent monooxygenases
37. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
38. Pharmacogenetics of acute azathroprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism
39. Timolol metabolism and debrisoquine hydroxylation polymorphism: a population study
40. Cyclosporin toxicity at therapeutic blood levels and cytochrome P450 III?
41. Drug reactions, enzymes and biochemical genetics
42. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature
43. The novel bilirubin/phenol UDP-glucuronosyltransferase UGT1 locus: implications for multiple nonhemolytic familial hyperbelirubinemia phenotypes
44. Variability of acetaminophen metabolism in Caucasians and Orientals
45. Hydroxylation of chlorzoxasone as a specific probe for human liver cytochrome P450 IIE1
46. Inheritance of human platelet thermolabile phenol sulphotransferase (TL PST) activity
47. Genetic polymorphism for human platelet thermostable phenol sulphotransferase (TS PST) activity
48. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP26 subfamily
49. Hydroxylation of warfarin by human liver cytochrome P450: a role for proteins encoded by CYP2C9 in etiology of anticoagulation drug interactions
50. Deficient (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9
51. Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UDP gene complex of a Crigler-Najjar type I patient
52. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin
53. Correlation between N-acetyltranserase activity and NAT2 genotype in Chinese males
54. Hereditary differences in the expression of the human glutathione S-transferase active on trans-stilbene oxide are due to gene deletion
55. An alternative test for acetylator phenotyping with caffeine
56. Familial pyrimidemia and pyrimidinuria associated with severe fluorouracil toxicity
57. Identification of a new CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabplizer (cytochrome P4502D6) phenotypes
58. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P450
59. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood
60. Methyltransferase pharmacogenetics
61. Genetic polymorphism of S-mephenytoin hydroxylation
62. Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects
63. Genetic polymorphism in human drug metabolism
64. Evidence for a new variant CYP2D6 allele, CYP2D6J, in a Japanese population associated with lower in vivo rates of sparteine metabolism
65. Molecular genetics of human aldehyde dehydrogenase
66. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation